GENERAL
Piramal Pharma Acquires Additional 40.67% Stake In Yapan Bio For ₹76 Cr
Piramal Pharma Ltd has completed the acquisition of an additional 40.67% stake in Yapan Bio Pvt Ltd for ₹76 crore, taking its total holding in the Hyderabad-based company to 74%. With the completion of the transaction on August 18, Yapan Bio has become a subsidiary of Piramal Pharma. The company is a contract development and […]
CW Bureau
·
Aug 19, 2026
GENERAL
CSIR-IICT, Viridis Biopharma Partner To Advance Diabetic Foot Therapy
CSIR–Indian Institute of Chemical Technology (CSIR-IICT), Hyderabad, has signed a technology transfer agreement with Viridis Biopharma Pvt Ltd for a phytopharmaceutical developed from Gymnema sylvestre for the treatment of diabetic foot ulcers. The technology also has potential applications in other chronic wounds and inflammatory skin disorders, opening up possibilities for wider therapeutic use. The development […]
CW Bureau
·
Aug 12, 2026
GENERAL
Lupin Carves Out 2 Cancer Therapy Programmes Into New US Venture
Global pharmaceutical major Lupin Ltd has announced the strategic spin-out of two of its oncology programmes into Kaveri Therapeutics Inc., a US-based clinical-stage oncology company, in a move aimed at accelerating the global development of targeted cancer therapies. Independent platform for oncology development The spin-out will be executed through Lupin Inc., the company’s wholly owned […]
CW Bureau
·
Jul 21, 2026
